THURSDAY, DECEMBER 8, 2016

BiondVax

Science Park, 14 Einstein Street PO Box 4143
Ness Ziona, Israel - 74140

BiondVax News

Israel approves patent application for universal flu vaccine

Israel recently approved a patent application for a new universal flu vaccine developed by BiondVax Pharmaceuticals Ltd., which will serve to expand and improve the company's international intellectual property portfolio. Read More »

BiondVax launches universal flu vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company based in Israel that creates and markets immunomodulation therapies to treat infectious diseases, recently launched a universal vaccine onto the market. Read More »

Universal flu vaccine patent approved in South Korea

BiondVax Pharmaceuticals Ltd. recently gained approval for its Multimeric Multi-Epitope Polypeptide Influenza Vaccines series patent in South Korea. Read More »

UNISEC consortium launches clinical trial for Universal Influenza Vaccine

UNISEC, the European consortium, recently announced that it has launched a clinical trial as the next phase of its research for a Universal Influenza Vaccine. Read More »

BiondVax Pharmaceuticals, Cytovance Biologics prepare flu vaccine for Phase III trials

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company focused on developing a universal flu vaccine, and Cytovance Biologics Inc., a contract development manufacturing company, have agreed to a Development and Manufacturing agreement for clinical batches of Biondvax’s M-001 universal flu vaccine for Phase III clinical trials. Read More »

BiondVax to launch clinical trial for flu vaccine

BiondVax Pharmaceuticals Ltd. has received regulatory clearance from the Hungarian Regulatory Authority and the Central Ethics Committee in Budapest to launch a Phase IIb clinical trial. Read More »

BiondVax plans Phase 2 test of pandemic primer vaccine

BiondVax Pharma recently announced that the National Institute of Allergy and Infectious Diseases (NIAID), which is a branch of the National Institutes of Health, has planned the launch of a Phase 2 trial of Multimeric-001 (M-001) in the U.S. Read More »

BiondVax universal flu vaccine improves immune response against H3N2

BiondVax Pharmaceuticals Ltd. recently announced that it has received results from a statistical analysis of a study that shows that BiondVax’s universal flu vaccine (M-001) has increased the immunogenicity of patients against the H3N2 influenza strain. Read More »

BiondVax universal flu vaccine shows positive independent results

BiondVax Pharmaceuticals Ltd. recently announced that the independent results of its universal flu vaccine (M-001) show effective immunogenicity against H3N2. Read More »

BiondVax sees positive results in M-001 flu vaccine clinical trial

BiondVax Pharmaceuticals, Ltd. said Monday that preliminary results are positive for its BVX-006 Phase II clinical trial for the company’s universal influenza vaccine candidate M-001. Read More »

BiondVax to present immunoassay workshop at EDUFULVAC event

Israel-based BiondVax Pharmaceuticals, Ltd. said Monday it will present a workshop Thursday and Friday in London at the invitation of EDUFULVAC, (EDUcate inFLUenza VACcine).  EDUFULVAC is a European consortium assembled by the European Vaccine Initiative in Germany and the National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH) in the United States. Read More »